Recombinant proteins, with their versatile applications in biotechnology, medicine, and research, play a pivotal role in pharmaceutical advancements such as the production of insulin, blood products, growth hormones, monoclonal antibodies, and vaccines. This innovative approach to protein manufacturing offers distinct advantages over traditional extraction methods, allowing for large-scale production with consistent quality and purity.
The global recombinant protein market is poised for significant growth, estimated to reach US$ 3131.37 million in 2023, with a projected CAGR of 7.3% from 2023 to 2030, as indicated by a recent report from Coherent Market Insights.
Market Dynamics:
A key driver of the recombinant protein market is the escalating demand from the pharmaceutical industry. These proteins find extensive use in the production of therapeutic drugs, vaccines, monoclonal antibodies, and other biologics, responding to the increasing prevalence of chronic diseases globally. Chronic diseases accounted for approximately 60% of total reported deaths in 2018, as per the World Health Organization (WHO). The market is further boosted by rising healthcare expenditure and increased R&D investments by biotechnology and pharmaceutical companies for the development of novel protein drugs. However, challenges arise from the high costs associated with recombinant protein production. The complexity of manufacturing processes, including cell culture, purification, and refolding, contributes to overall expenses. Technological advancements in production techniques are crucial for cost reduction and are expected to drive market growth in the coming years.
Segment Analysis:
The global recombinant protein market is segmented by product type, application, end-user, and region. The therapeutics segment is anticipated to dominate the market during the forecast period, driven by increased research and development activities in pharmaceutical and biopharmaceutical industries. Therapeutic recombinant proteins are extensively used in the treatment of diseases such as cancer, infectious diseases, and hormonal disorders.
PEST Analysis:
- Political: Government regulations supporting research and development activities in the biotechnology and pharmaceutical sectors will aid market growth. Stringent regulations for recombinant protein approval may pose challenges.
- Economic: Rising healthcare spending, an increase in chronic diseases, and a growing geriatric population drive the demand for recombinant proteins. However, high manufacturing costs present a challenge.
- Social: Growing public awareness about recombinant therapeutics and a rising demand for affordable treatment options contribute to market growth.
- Technological: Advancements in gene expression systems, cell culture methods, and purification technologies have increased production yields, reducing costs. Ongoing research on gene therapy and stem cell therapy also supports market growth.
Key Takeaways:
The global recombinant protein market is poised for high growth, fueled by the rising prevalence of chronic diseases and the increasing demand for biologics and biosimilars as affordable treatment options.
Geographically, North America is expected to dominate the market, driven by strong biotechnology research in the US and Canada. Europe is anticipated to hold a significant market share, while the Asia Pacific region is poised for the fastest growth, supported by rising healthcare spending, a growing geriatric population, and increased focus from international players in emerging nations like India and China.
Key Players:
Major players in the recombinant protein market, such as Merck KGaA, Allergan plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical, and Mylan N.V, are actively engaged in expanding manufacturing facilities and investing in R&D for innovative recombinant proteins to address various diseases.
For More details on the topic:
www.ukwebwire.com/recombinant-protein-market-demand-share-analysis/
Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology.Key Drivers of Global Recombinant Proteins MarketIncrease in research and development expenditure on biologics drug from major market players is a major factor driving the global recombinant proteins market.
Recombinant proteins require less clinical trial time as compared to small molecules, which helps enhance patient protection and provides pharmaceutical companies with longer exclusive sales time.Recombinant proteins are employed in the treatment of major chronic diseases such as cancer, cardiovascular diseases, endocrine diseases, and viral diseases.
Globally, about 1 in 6 deaths is due to cancer.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=80354Hormone Segment to be Highly PromisingBased on product type, the global recombinant proteins market can be segmented into hormone, growth factor, cytokines, enzymes, and othersThe hormone segment accounted for a prominent share of the global recombinant proteins market in 2019.
It is anticipated to expand significantly during the forecast period.Recombinant protein containing products are used in the treatment of diseases such as diabetes, cancer, and inflammatory diseases.
According to International Diabetes Federation, in 2019, approx.
463 million adults (20-79 years) were living with diabetes, and this value is projected to reach 700 million by 2045.Request COVID Analysis on Recombinant Proteins Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=80354 North America to Dominate Global Recombinant Proteins MarketIn terms of region, the global recombinant proteins market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & AfricaNorth America dominated the global recombinant proteins market in 2019.
